[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].

Objective To evaluate the correlation of clinical effect and prognosis between patients with metastatic colorectal cancer (mCRC) and different K-ras status.Methods The clinical characteristics,chemotherapeutic regimens and survival of 153 mCRC patients with different K-ras status were analyzed retrospectively.Results The median overall survival (OS) in patients without K-ras mutation were 31.7 months,significantly longer than 21.3 months in the patients with K-ras mutation (P =0.037).The median progression-free survival (PFS) and OS in patients who received chemotherapy followed by anti-EGFR antibody treatment were 11.5 and 39.3 months,respectively,significantly longer as compared with the PFS and OS in those received chemotherapy in combination with anti-EGFR antibody concomitantly (5.7,P =0.02,and 28.7 months,P =0.034,respectively).Conclusions K-ras status is a prognostic biomarker for mCRC patients treated with anti-EGFR antibody.The combination settings of antiEGFR in combination with chemotherapy may improve survival of mCRC patients with wild-type K-ras status. Key words: Colorectal neoplasms ;  Genes, K-ras ;  Targeted therapy ;  Receptor, epidermal growth factor